Answers are grounded in this paper and cite their sources.
In 10 clinical trials involving 4747 patients, among those who received the PCSK9 inhibitor alirocumab, antidrug antibodies developed in 5.1%, although no significant effect was seen on the reduction in LDL cholesterol levels.
No takes yet. Share an insight, caveat, or question.
Roth et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: